Compare Franco-Nevada Corporation (FNV) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Franco-Nevada Corporation vs Twist Bioscience Corp — how do they compare? Franco-Nevada Corporation trades at $241.16 (market cap $45.36B), while Twist Bioscience Corp trades at $140.5 (market cap $9.82B). The key difference: Franco-Nevada Corporation is far larger — about 4.6× Twist Bioscience Corp's market cap, and Franco-Nevada Corporation pays a 0.75% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Franco-Nevada Corporation for 0 Days and Twist Bioscience Corp for 27 Days on average.
| FNV | TWST | |
|---|---|---|
Market Cap | $45.36B | $9.82B |
Volume | 787,841 | 2,115,226 |
Sector | Basic Materials | Health |
52-Week High | $280.82 | $205.00 |
52-Week Low | $183.97 | $25.45 |
Typical Hold Time | 0 Days | 27 Days |
Enterprise Value | $44.34B | $9.75B |
Dividend Yield | 0.75% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Franco-Nevada (FNV) trades at $243.85, showing a slight decline of 0.77% over the past day. The stock is positioned neutrally from a technical perspective, with key support near $242 and resistance at $246. Fundamentally, the company exhibits strong profitability with a net income margin of 63.79% and has beaten earnings expectations in two of the last three quarters. Recent news highlights portfolio expansion, including a significant investment in the Bullabulling Gold Project and positive developments regarding the potential restart of the Cobre Panama mine.
The outlook for FNV is supported by analyst consensus, with a price target of $275 suggesting potential upside. Key opportunities include revenue growth from new projects and high profit margins. Risks involve execution on new investments, commodity price volatility, and geopolitical factors affecting mining operations. The balanced analyst rating split indicates cautious optimism for future performance.
TWST trades at $151.33, down 0.35% today, near its consensus price target of $153.70. The stock shows a bullish technical signal despite recent earnings misses, with revenue growth improving from $204M in 2022 to $377M in 2025. However, profitability remains a challenge with a net income margin of -31.66% and negative cash flows. Recent news highlights its role in Eli Lilly's AI-driven drug discovery platform, fueling investor optimism in the healthtech sector.
The outlook balances strong revenue growth and AI partnerships against persistent losses and high valuation multiples. Investment appeal hinges on the company's ability to translate top-line expansion into profitability, with analyst consensus leaning bullish but execution risks remaining elevated for stockholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Franco-Nevada Corporation
Franco-Nevada Corporation is a royalty and streaming company that finances mining and energy projects in exchange for royalty payments or the right to purchase output at set prices, holding a diversified portfolio across Precious Metals, Other Mining, and Energy (oil, gas, and natural gas liquids).
Read more on FNV →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
